MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment

Metadherin (MTDH) is identified as an oncogene in multiple cancers including breast cancer, bladder cancer and endometrial cancer. However, the function of MTDH in multiple myeloma (MM) is still unexplored. In this study, we disclose that MTDH is an oncogene in MM. This is characterized by an elevation mRNA level of MTDH and chromosomal gain of MTDH locus in MM cells compared to normal samples. Moreover, MTDH expression significantly increased in MMSET translocation (MS) subgroup, one of the high-risk subgroups in MM, and was significantly correlated with MM patients' poor outcomes in Total Therapy 2 (TT2) cohort. Further knockdown of MTDH expression by shRNA in MM cells induced cell apoptosis, inhibited MM cells growth in vitro and decreased xenograft tumor formation in vivo. Interestingly, opposite to TT2, MM patients with high-MTDH expression showed favorable survival outcomes in the TT3 cohort, while Bortezomib treatment was the major difference between TT2 and TT3 cohort. Furthermore we proved that Bortezomib suppressed pre- and post-transcription levels of MTDH expression of MM cells in vitro and in vivo. Finally, our studies demonstrated that MTDH is a transcriptional gene of MMSET/NFκB /MYC signaling in MM cells, which is inhibited by Bortezomib treatment.

[1]  L. Chin,et al.  High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. , 2006, Cancer cell.

[2]  C. Gu,et al.  BUB1B promotes multiple myeloma cell proliferation through CDC20/CCNB axis , 2015, Medical Oncology.

[3]  Yibin Kang,et al.  The Multifaceted Role of MTDH/AEG-1 in Cancer Progression , 2009, Clinical Cancer Research.

[4]  J. T. Babcock,et al.  Mammalian Target of Rapamycin Complex 1 (mTORC1) Enhances Bortezomib-induced Death in Tuberous Sclerosis Complex (TSC)-null Cells by a c-MYC-dependent Induction of the Unfolded Protein Response* , 2013, The Journal of Biological Chemistry.

[5]  D. Saur,et al.  MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib , 2014, Nucleic acids research.

[6]  F. Zhan,et al.  Decreased ferroportin promotes myeloma cell growth and osteoclast differentiation. , 2015, Cancer research.

[7]  John Crowley,et al.  The molecular classification of multiple myeloma. , 2006, Blood.

[8]  B. Barlogie,et al.  The Arkansas approach to therapy of patients with multiple myeloma. , 2007, Best practice & research. Clinical haematology.

[9]  L. Bruhn,et al.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. , 2007, Cancer cell.

[10]  O. Stephens,et al.  Prediction of cytogenetic abnormalities with gene expression profiles. , 2012, Blood.

[11]  Yongsheng Huang,et al.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.

[12]  Z. Xie,et al.  MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib , 2015, Leukemia.

[13]  P. Fisher,et al.  Activation of the nuclear factor kappaB pathway by astrocyte elevated gene-1: implications for tumor progression and metastasis. , 2006, Cancer research.

[14]  C. Myers,et al.  Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model , 2013, Molecular Cancer Therapeutics.

[15]  Eugenia G. Giannopoulou,et al.  Histone Methyltransferase MMSET/NSD2 Alters EZH2 Binding and Reprograms the Myeloma Epigenome through Global and Focal Changes in H3K36 and H3K27 Methylation , 2014, PLoS genetics.

[16]  B. Barlogie,et al.  Cytogenetic findings in 200 patients with multiple myeloma. , 1995, Cancer genetics and cytogenetics.

[17]  L. Staudt,et al.  The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. , 2011, Blood.

[18]  F. Zhan,et al.  NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. , 2013, Cancer cell.

[19]  L. Staudt,et al.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. , 2007, Cancer cell.

[20]  John Crowley,et al.  Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. , 2011, Blood.

[21]  F. Zhan,et al.  ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma , 2014, Leukemia.

[22]  E. Tokunaga,et al.  Overexpression of metadherin/MTDH is associated with an aggressive phenotype and a poor prognosis in invasive breast cancer , 2012, Breast Cancer.

[23]  W. Schulz,et al.  MTDH/AEG-1 contributes to central features of the neoplastic phenotype in bladder cancer. , 2014, Urologic oncology.

[24]  Michael Reiss,et al.  MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. , 2009, Cancer cell.

[25]  M. Höglund,et al.  A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age‐ and sex‐related differences , 2003, British journal of haematology.

[26]  K. Anderson,et al.  Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. , 2009, Blood.

[27]  J. Li,et al.  Metadherin is a novel prognostic marker for bladder cancer progression and overall patient survival , 2012, Asia-Pacific journal of clinical oncology.

[28]  F. Khuri,et al.  Proteasome Inhibitor PS-341 (Bortezomib) Induces Calpain-dependent IκBα Degradation* , 2010, Journal of Biological Chemistry.

[29]  B. Barlogie,et al.  Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma. , 2014, Blood.

[30]  R. Kyle,et al.  The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. , 1985, Blood.

[31]  B. Barlogie,et al.  Eight‐year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1 , 2008, British journal of haematology.

[32]  A. Al-Katib,et al.  Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes , 2007, American journal of hematology.

[33]  Tao Chen,et al.  Apoptosis of human non-small-cell lung cancer A549 cells triggered by evodiamine through MTDH-dependent signaling pathway , 2015, Tumor Biology.

[34]  P. Fisher,et al.  Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc , 2006, Proceedings of the National Academy of Sciences.

[35]  Derek Y. Chiang,et al.  Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. , 2009, The Journal of clinical investigation.

[36]  Dong-Chul Kang,et al.  Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration. , 2007, Pharmacology & therapeutics.